| Tracie Ella Filipek, | |
|
110 Wright Rd, Beckley, WV 25801-6954 | |
| (304) 673-1810 | |
| Not Available |
| Full Name | Tracie Ella Filipek |
|---|---|
| Gender | Female |
| Speciality | Case Manager/care Coordinator |
| Location | 110 Wright Rd, Beckley, West Virginia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376813337 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YP2500X | Counselor - Professional | (* (Not Available)) | Secondary |
| 171M00000X | Case Manager/care Coordinator | (West Virginia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Tracie Ella Filipek, 110 Wright Rd, Beckley, WV 25801-6954 Ph: (304) 673-1810 | Tracie Ella Filipek, 110 Wright Rd, Beckley, WV 25801-6954 Ph: (304) 673-1810 |
News Archive
Inovio Pharmaceuticals, Inc. announced today that Dr. Niranjan Sardesai, COO, will participate on a panel of senior vaccine experts at the 2012 BIO International Convention,the largest global event for the biotechnology industry. Dr. J. Joseph Kim, President and CEO, will present an overview of the company at the Marcum Microcap Conference, which is designed for investors interested in micro-cap companies.
"California is going to have to pay a $51.8 billion bill for health and dental benefits for state retirees, says state Controller John Chiang in a report to the Legislature Tuesday. 'Even as we try to claw our way out of the recession and provide needed cash to the state's coffers, we cannot ignore the promise that we made to pay health and dental benefits for current state employees and retirees,' says Mr. Chiang" (2/9).
Researchers may be able to develop an antidepressant which takes effect almost immediately by directly targeting novel molecules in the brain instead of taking a less direct route, which can lead to longer times for medication to take effect, according to a new study presented at the American College of Neuropsychopharmacology (ACNP) annual meeting.
Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study (RIBBON 2) of Avastin® (bevacizumab) in women who had previously been treated with initial (first-line) chemotherapy for advanced HER2-negative breast cancer and needed additional (second-line) treatment.
Four studies that highlight significant advances in treatment and survival outcomes for patients with various forms of thrombocytopenia, a group of bleeding disorders characterized by a low number of platelets in the blood, were presented December 6 during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA.
› Verified 9 days ago